Holen Sie sich die Stockscreener-App
2.4399
1.21%
-0.0401
Schlusskurs vom Vortag:
$2.48
Offen:
$2.48
24-Stunden-Volumen:
285.24K
Relative Volume:
0.07
Marktkapitalisierung:
$607.34M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-8.7139
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
-0.41%
1M Leistung:
+33.88%
6M Leistung:
+31.72%
1J Leistung:
+99.19%
1-Tages-Spanne:
$2.425
$2.49
1-Wochen-Bereich:
$2.35
$2.90
52-Wochen-Spanne:
$0.80
$2.90
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie AKBA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.445 | 607.34M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
158.41 | 66.72B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.51 | 48.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.85 | 47.74B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.16 | 18.49B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.99 | 13.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - GuruFocus
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewswire
Akebia projects Vafseo rollout to double patient access by Q4 2025 - MSN
Akebia Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics: Q1 Earnings Snapshot - New Haven Register
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... - Yahoo Finance
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ... By GuruFocus - Investing.com Canada
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and Strategic Market Penetration - GuruFocus
Akebia Therapeutics Reports Strong Q1 2025 Performance - TipRanks
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Akebia Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Akebia Therapeutics, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Akebia Therapeutics (AKBA) Sees Strong Q1 Revenue Growth Fueled by Vafseo - GuruFocus
Akebia Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Akebia Therapeutics beats Q1 2025 estimates, stock surges - Investing.com Australia
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Akebia (AKBA) Surpasses Revenue Expectations with Strong Vafseo Debut | AKBA Stock News - GuruFocus
Akebia Therapeutics Inc Q1 2025 Earnings: EPS of $0.04, Revenue Surges to $57.3 Million, Beating Estimates - GuruFocus
Akebia Therapeutics, Inc. SEC 10-Q Report - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings To Watch: Akebia Therapeutics Inc (AKBA) Reports Q1 2025 Result - Yahoo Finance
Akebia Therapeutics Announces Multiple Positive Business Updates - ADVFN
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 38% Share Price Rise - simplywall.st
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - ADVFN
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights - marketscreener.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Expands Team: Grants $2.41 Stock Options to 8 New Strategic Hires - Stock Titan
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Akebia Therapeutics, Inc. Announces First Quarter 2025 Financial Results Release and Conference Call Details - Nasdaq
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business ... - Bluefield Daily Telegraph
Akebia (AKBA) Secures Strong Position with Vafseo Launch for Ane - GuruFocus
Leerink raises Akebia stock to outperform with $7 target By Investing.com - Investing.com Canada
Leerink Partners Initiates Coverage of Akebia Therapeutics (AKBA) with Outperform Recommendation - Nasdaq
Akebia (AKBA) Secures Strong Position with Vafseo Launch for Anemia Treatment | AKBA Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - ADVFN
Lobbying Update: $45,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock - Barchart.com
US High Growth Tech Stocks to Watch in 2023 - Yahoo Finance
Akebia Therapeutics : Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones - MarketScreener
Akebia Therapeutics gets EU positive recommendation for Xoanacyl - MSN
Akebia Therapeutics Announces Positive Opinion of European - GlobeNewswire
EMA panel endorses Akebia’s kidney disease treatment By Investing.com - Investing.com Australia
EMA panel endorses Akebia’s kidney disease treatment - Investing.com India
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
0.99%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):